Astec LifeSciences Limited — Board Meeting, 23-04-2025: Outcome of Board Meeting

The Board of Directors of Astec LifeSciences Limited has approved the audited financial results for the quarter and financial year ended 31st March, 2025. The standalone revenue from operations stood at ₹119.53 crore, with a total loss of ₹160.99 crore for the period. The consolidated results mirrored this trend, with a total income of ₹120.32 crore and a loss of ₹160.79 crore. The Board also approved the 31st Annual General Meeting set for 28th July, 2025, and plans to seek shareholder approval for related party transactions with Godrej Agrovet Limited. Details on the statutory auditors' reports indicate an unmodified opinion.